Julie Norville co-founded and co-runs JURA Bio, Inc., an early-stage therapeutics start up focusing on developing and delivering cell-based therapies for the treatment of autoimmune and immune-related neurodegenerative disease. Before JURA, Norville was a Research Fellow in Genetics at the laboratory of George Church at Harvard Medical School, performing some of the first demonstrations of CRISPR in eukaryotes (human cells, plants, and yeast) and developing tools for the radical recoding of genomes.
For her doctoral studies in Electrical Engineering & Computer Science (EECS) at MIT, Julie worked with Angela Belcher, Thomas Knight, and Gerald Sussman to modularly design biological systems at the DNA (using libraries of parts), protein (using proteins that programmably crystallize in the presence of calcium), and cell level (using cells embedded in paper and interleaved with membranes to allow communication). She is a recipient of a National Academy Keck Futures Initiative grant. She built one of the first photovoltaics made using a membrane protein from photosynthesis, developed fabrication techniques for building labs-on-chips, and worked at Intel’s semiconductor fab in Mask Operations in Santa Clara, California.